Patient characteristics
| Pt . | Age/Sex . | Primary diagnosis . | Time to relapse after transplant/type . | HLA match with donor . | Treatment received after relapse posttransplant . | Absolute T cell count/ALC at time of infusion (per uL) . | Status of disease at T-cell infusion . |
|---|---|---|---|---|---|---|---|
| 1 | 23/F | B-ALL/Ph+ | 9 mo/MRD | 6/6 | Hyper CVAD (MTX and Ara-C) | 992/1269 | Detection of bcr/abl transcripts |
| Dasatinib | |||||||
| 2 | 59/M | B-CLL/Richter’s | 3 mo/MUD | 13/14 | Lenalidomide | 35/1154 | Lymphadenopathy; 16% circulating CD19+CD5+ cells |
| Hyper CVAD with rituximab × 2 | |||||||
| Ofatumumab with methylprednisolone | |||||||
| Radiation | |||||||
| Hyper CVAD without vincristine | |||||||
| 3 | 57/M | B-CLL/17p deletion | 11 y/MRD | 6/6 | DLI | 4897/10155 | 25% Circulating CD19+CD5+ cells |
| Rituximab | |||||||
| Lenalidomide | |||||||
| Bendamustine | |||||||
| 4 | 9/M | Pre–B-ALL | 1 y/MRD | 10/10 | AALL07p1 (standard 4-drug induction with bortezomib) | 313/4962 | 0.5% Circulating blasts |
| Steroids | |||||||
| Vincristine | |||||||
| 5 | 49/M | B-CLL/Richter’s | 14 mo/MRD | 14/14 | Hyper CVAD | 731/4501 | Lymphadenopathy; 64% circulating CD19+CD5+ cells |
| Rituximab | |||||||
| Dexamethasone | |||||||
| Methylprednisolone | |||||||
| Lenalidomide | |||||||
| Ofatumumab | |||||||
| 6 | 59/M | B-CLL/17p deletion | Immediate/MRD | 10/10 | DLI × 4 | 993/12232 | Lymphadenopathy; splenomegaly; 81% circulating CD19+CD5+ cells |
| Lenalidomide | |||||||
| Ofatumumab × 8 | |||||||
| 7 | 40/F | Pre-BALL/Ph+ | No relapse/MUD | 10/10 | — | 2921/4500 | CR |
| 8 | 12/F | B-ALL | No relapse/MUD | 9/10 | — | 1913/4030 | CR |
| Pt . | Age/Sex . | Primary diagnosis . | Time to relapse after transplant/type . | HLA match with donor . | Treatment received after relapse posttransplant . | Absolute T cell count/ALC at time of infusion (per uL) . | Status of disease at T-cell infusion . |
|---|---|---|---|---|---|---|---|
| 1 | 23/F | B-ALL/Ph+ | 9 mo/MRD | 6/6 | Hyper CVAD (MTX and Ara-C) | 992/1269 | Detection of bcr/abl transcripts |
| Dasatinib | |||||||
| 2 | 59/M | B-CLL/Richter’s | 3 mo/MUD | 13/14 | Lenalidomide | 35/1154 | Lymphadenopathy; 16% circulating CD19+CD5+ cells |
| Hyper CVAD with rituximab × 2 | |||||||
| Ofatumumab with methylprednisolone | |||||||
| Radiation | |||||||
| Hyper CVAD without vincristine | |||||||
| 3 | 57/M | B-CLL/17p deletion | 11 y/MRD | 6/6 | DLI | 4897/10155 | 25% Circulating CD19+CD5+ cells |
| Rituximab | |||||||
| Lenalidomide | |||||||
| Bendamustine | |||||||
| 4 | 9/M | Pre–B-ALL | 1 y/MRD | 10/10 | AALL07p1 (standard 4-drug induction with bortezomib) | 313/4962 | 0.5% Circulating blasts |
| Steroids | |||||||
| Vincristine | |||||||
| 5 | 49/M | B-CLL/Richter’s | 14 mo/MRD | 14/14 | Hyper CVAD | 731/4501 | Lymphadenopathy; 64% circulating CD19+CD5+ cells |
| Rituximab | |||||||
| Dexamethasone | |||||||
| Methylprednisolone | |||||||
| Lenalidomide | |||||||
| Ofatumumab | |||||||
| 6 | 59/M | B-CLL/17p deletion | Immediate/MRD | 10/10 | DLI × 4 | 993/12232 | Lymphadenopathy; splenomegaly; 81% circulating CD19+CD5+ cells |
| Lenalidomide | |||||||
| Ofatumumab × 8 | |||||||
| 7 | 40/F | Pre-BALL/Ph+ | No relapse/MUD | 10/10 | — | 2921/4500 | CR |
| 8 | 12/F | B-ALL | No relapse/MUD | 9/10 | — | 1913/4030 | CR |
MUD, matched unrelated donor; MRD, matched related donor.